Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s...
Harbour BioMed Receives FDA Clearance for Phase I Trial of Novel B7H4xCD3 Bispecific Antibody HBM7004
Harbour BioMed (HKG: 2142) announced it has received clearance from the U.S. Food and Drug...
Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic partnership with...
Johnson & Johnson Terminates Two CAR-T Development Programs Amid Portfolio Prioritization
Johnson & Johnson (J&J, NYSE: JNJ) announced the termination of development programs for JNJ-9530, a...
China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
The National Drug Alliance Procurement Office, administrator of China’s volume-based procurement (VBP) program, announced the...
Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
Harbour BioMed (HKG: 2142) announced its participation in a $165 million cross financing round for...
Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...
Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing...
Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) reported first-quarter 2026 total revenues of $99.6 million,...
Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
Viatris Inc. (NASDAQ: VTRS) announced first-quarter 2026 total revenues of $3.5 billion, representing an 8%...
Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a...
Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced a definitive agreement to acquire PathAI, a leading...
Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA)...
Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb...
Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of...
Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III...
China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
China’s National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly...
China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access
China’s National Health Commission (NHC) released comprehensive “Implementation Opinions on Reforming and Improving the Supply...
Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...
GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
GlaxoSmithKline plc (GSK, NYSE: GSK) released its first-quarter 2026 financial results on May 6, 2026,...